The DOI matches its Crossref record.
Neuroprotection with noninvasive neurotrophin delivery to the brain
Open accessAbstract
Brain-derived neurotrophic factor (BDNF) is neuroprotective in the ischemic hippocampus if the neurotrophin is injected directly into the brain. However, the efficacy of BDNF via peripheral (i.v.) administration is limited by the lack of transport of the neurotrophin through the brain capillary wall, which makes up the blood-brain barrier (BBB) in vivo . The present studies describe a molecular reformulation of BDNF that incorporates polyethylene glycol (PEG) moieties at surface carboxyl residues, to optimize plasma pharmacokinetics, and links pegylated BDNF to the OX26 mAb, which undergoes receptor-mediated transport through the BBB via the brain capillary endothelial transferrin receptor. The BDNF-PEG 2000-biotin conjugated to OX26/streptavidin was administered i.v. daily to rats for 1 week after a 12-min period of transient forebrain ischemia. The neuronal density in the CA1 sector of the hippocampus was decreased 68 ± 10% at 1 week after the ischemia. There was no neuroprotective effect of the unconjugated BDNF or unconjugated OX26 mAb. However, the hippocampal CA1 neuronal density was normalized by i.v. administration of the BDNF-PEG 2000-biotin conjugated to OX26/streptavidin. These studies demonstrate that peripherally administered BDNF may have neuroprotective effects in brain, if the neurotrophin is reformulated to ( i ) optimize plasma pharmacokinetics with carboxyl-directed pegylation, and ( ii ) enable transport through the BBB by coupling to brain transport vectors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798
“in adult rats subjected to transient forebrain ischemia after delayed intravenous administration.(55) • BDNF reduces stroke volume 65-70% in adult rats”
Self-citationPardridge, W. M. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.10.013 · Cited by 1,191
Self-citationTargeted Drug Delivery via the Transferrin Receptor-Mediated Endocytosis Pathway
Qian, Z. M., Li, H., Sun, H., & Ho, K. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.4.561 · Cited by 1,019
The Role of Markers of Inflammation in Traumatic Brain Injury
Woodcock, T., & Morganti-Kossmann, M. C. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00018 · Cited by 712
Almeida, R. D., Manadas, B. J., Melo, C. V., Gomes, J. R., Mendes, C. S., Grãos, M. M., Carvalho, R. F., Carvalho, A. P., & Duarte, C. B. (2005) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401662 · Cited by 583
Drug Delivery Systems, CNS Protection, and the Blood Brain Barrier
Upadhyay, R. K. (2014) · BioMed Research International · doi:10.1155/2014/869269 · Cited by 528
Delivery of Neurotrophic Factors to the Central Nervous System: Pharmacokinetic Considerations
Thorne, R. G., & Frey, W. H. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140120-00003 · Cited by 487
Getting into the Brain: Approaches to Enhance Brain Drug Delivery
Patel, M. M., Goyal, B. R., Bhadada, S. V., Bhatt, J. S., & Amin, A. F. (2009) · CNS Drugs · doi:10.2165/0023210-200923010-00003 · Cited by 461
Pardridge, W. M. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9324-2 · Cited by 447
Self-citationBlood-brain barrier biology and methodology
Pardridge, W. M. (1999) · Journal of Neurovirology · doi:10.3109/13550289909021285 · Cited by 445
Self-citationDrug and gene targeting to the brain with molecular trojan horses
Pardridge, W. M. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd725 · Cited by 439
Self-citationThe Neurotrophin Family of Neurotrophic Factors: An Overview
Skaper, S. D. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-536-7_1 · Cited by 372
Targeting the transferrin receptor for brain drug delivery
Johnsen, K. B., Burkhart, A., Thomsen, L. B., Andresen, T. L., & Moos, T. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.101665 · Cited by 370
Ploughman, M., Windle, V., MacLellan, C. L., White, N., Doré, J. J., & Corbett, D. (2009) · Stroke · doi:10.1161/strokeaha.108.531806 · Cited by 362
Schäbitz, W.-R., Sommer, C., Zoder, W., Kiessling, M., Schwaninger, M., & Schwab, S. (2000) · Stroke · doi:10.1161/01.str.31.9.2212 · Cited by 325
Csuka, E., Morganti-Kossmann, M. C., Lenzlinger, P. M., Joller, H., Trentz, O., & Kossmann, T. (1999) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(99)00148-4 · Cited by 324
Lee, H. J., Engelhardt, B., Lesley, J., Bickel, U., & Pardridge, W. M. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35388-1 · Cited by 287
Self-citationSchäbitz, W.-R., Berger, C., Kollmar, R., Seitz, M., Tanay, E., Kiessling, M., Schwab, S., & Sommer, C. (2004) · Stroke · doi:10.1161/01.str.0000119754.85848.0d · Cited by 283
Connolly, A. M., Chez, M., Streif, E. M., Keeling, R. M., Golumbek, P. T., Kwon, J. M., Riviello, J. J., Robinson, R. G., Neuman, R. J., & Deuel, R. M. K. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.07.004 · Cited by 263
Molecular Trojan horses for blood–brain barrier drug delivery
PARDRIDGE, W. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.06.001 · Cited by 260
Self-citationFunctional recovery with recombinant human IGF1 treatment in a mouse model of Rett syndrome
Castro, J., Garcia, R. I., Kwok, S., Banerjee, A., Petravicz, J., Woodson, J., Mellios, N., Tropea, D., & Sur, M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1311685111 · Cited by 242
A Historical Review of Brain Drug Delivery
Pardridge, W. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061283 · Cited by 219
Self-citationshRNA and siRNA delivery to the brain
Pardridge, W. M. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.03.008 · Cited by 176
Zhang, Y., & Pardridge, W. M. (2001) · Stroke · doi:10.1161/01.str.32.6.1378 · Cited by 175
Self-citationPeptide therapeutics for CNS indications
McGonigle, P. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.10.014 · Cited by 95
Enhancing autophagy in Alzheimer's disease through drug repositioning
Eshraghi, M., Ahmadi, M., Afshar, S., Lorzadeh, S., Adlimoghaddam, A., Rezvani Jalal, N., West, R., Dastghaib, S., Igder, S., Torshizi, S. R. N., et al. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108171 · Cited by 89
Evolving new-age strategies to transport therapeutics across the blood-brain-barrier
Choudhari, M., Hejmady, S., Narayan Saha, R., Damle, S., Singhvi, G., Alexander, A., Kesharwani, P., & Kumar Dubey, S. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120351 · Cited by 74
Metadata
- Authors
- Wu, D., & Pardridge, W. M.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1999-01-05
- Volume
- 96
- Issue
- 1
- Pages
- 254-259
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2001867528
- Cited by
- 205
- References
- 0
- FWCI
- 5.03
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.